TY - JOUR
T1 - Synthesis, Physicochemical Characterization using a Facile Validated HPLC Quantitation Analysis Method of 4-Chloro-phenylcarbamoyl-methyl Ciprofloxacin and Its Biological Investigations
AU - Al-Hakkani, Mostafa F.
AU - Ahmed, Nourhan
AU - Abbas, Alaa A.
AU - Hassan, Mohammad H.A.
AU - Aziz, Hossameldin A.
AU - Elshamsy, Ali M.
AU - Khalifa, Hazim O.
AU - Abdelshakour, Mohamed A.
AU - Saddik, Mohammed S.
AU - Elsayed, Mahmoud M.A.
AU - Sabet, Marwa A.
AU - El-Mokhtar, Mohamed A.
AU - Alsehli, Mosa
AU - Amin, M. S.
AU - Abu-Dief, Ahmed M.
AU - Mohammed, Hamada H.H.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/10
Y1 - 2023/10
N2 - A novel derivative of ciprofloxacin (Cpx) was synthesized and characterized using various analytical techniques, including FT-IR spectroscopy, UV-Vis spectroscopy, TEM and SEM analysis, 1H NMR, 13C NMR, and HPLC analysis. The newly prepared Cpx derivative (Cpx-Drv) exhibited significantly enhanced antibacterial properties compared to Cpx itself. In particular, Cpx-Drv demonstrated a 51% increase in antibacterial activity against S. aureus and a 30% improvement against B. subtilis. It displayed potent inhibitory effects on topoisomerases II (DNA gyrase and topoisomerase IV) as potential molecular targets, with IC50 values of 6.754 and 1.913 µg/mL, respectively, in contrast to Cpx, which had IC50 values of 2.125 and 0.821 µg/mL, respectively. Docking studies further supported these findings, showing that Cpx-Drv exhibited stronger binding interactions with the gyrase enzyme (PDB ID: 2XCT) compared to the parent Cpx, with binding affinities of −10.3349 and −7.7506 kcal/mole, respectively.
AB - A novel derivative of ciprofloxacin (Cpx) was synthesized and characterized using various analytical techniques, including FT-IR spectroscopy, UV-Vis spectroscopy, TEM and SEM analysis, 1H NMR, 13C NMR, and HPLC analysis. The newly prepared Cpx derivative (Cpx-Drv) exhibited significantly enhanced antibacterial properties compared to Cpx itself. In particular, Cpx-Drv demonstrated a 51% increase in antibacterial activity against S. aureus and a 30% improvement against B. subtilis. It displayed potent inhibitory effects on topoisomerases II (DNA gyrase and topoisomerase IV) as potential molecular targets, with IC50 values of 6.754 and 1.913 µg/mL, respectively, in contrast to Cpx, which had IC50 values of 2.125 and 0.821 µg/mL, respectively. Docking studies further supported these findings, showing that Cpx-Drv exhibited stronger binding interactions with the gyrase enzyme (PDB ID: 2XCT) compared to the parent Cpx, with binding affinities of −10.3349 and −7.7506 kcal/mole, respectively.
KW - antibacterial
KW - anticancer
KW - ciprofloxacin
KW - DNA gyrase
KW - docking studies
KW - HPLC
KW - validation
UR - http://www.scopus.com/inward/record.url?scp=85174699777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174699777&partnerID=8YFLogxK
U2 - 10.3390/ijms241914818
DO - 10.3390/ijms241914818
M3 - Article
C2 - 37834266
AN - SCOPUS:85174699777
SN - 1661-6596
VL - 24
JO - International journal of molecular sciences
JF - International journal of molecular sciences
IS - 19
M1 - 14818
ER -